- 期刊
Rosiglitazone, an Agonist of PPARγ, Inhibits Non-Small Cell Carcinoma Cell Proliferation In Part through Activation of Tumor Sclerosis Complex-2
延伸閱讀
- Ha, Y. P. (2012). Hepatocyte growth factor activator inhibitor type 2 (HAI-2) acts as a negative regulator for cancer stem cell-related factors in prostate cancer cells [master's thesis, National Taiwan University]. Airiti Library. https://doi.org/10.6342/NTU.2012.01952
- Yen, M. H., Lee, Y. M., Huang, T. F., & Sheu, J. R. (1995). Effect of DC-015, a Novel Potent and Selective α1-Adrenoceptor Antagonist, Comparison with Prazosin on Noradrenaline-Induced Platelet Aggregation. The Chinese Journal of Physiology, 38(2), 93-98. https://www.airitilibrary.com/Article/Detail?DocID=03044920-199506-38-2-93-98-a
- 張雪玲（2008）。The cytotoxic effect and molecular mechanism of new flavonoid compound, protoapigenone, against ovarian and prostate cancer cells.〔博士論文，高雄醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0011-2612200810553400
- NAVID, F., MISCHEN, B. T., & HELMAN, L. J. (2004). Low dose histone deacetylase inhibitor, depsipeptide (FR901228), promotes adenoviral transduction in human rhabdomyosarcoma cell lines. Sarcoma, 2004(), 25-30. https://doi.org/10.1080/13577140410001679220
- Burton, J. D., Goldenberg, D. M., & Blumenthal, R. D. (2008). Potential of Peroxisome Proliferator-Activated Receptor Gamma Antagonist Compounds as Therapeutic Agents for a Wide Range of Cancer Types. PPAR Research, 2008(), 692-698-062. https://doi.org/10.1155/2008/494161